Savara (SVRA) Total Liabilities (2010 - 2026)
Savara (SVRA) reported Total Liabilities of $45.6 million for Q1 2026, up 9.98% year-over-year from $41.5 million in Q1 2025, and down 9.34% on a QoQ basis from $50.3 million in Q4 2025.
Savara (SVRA) has 17 years of Total Liabilities data on file, last reported at $45.6 million in Q1 2026.
- Quarterly Total Liabilities rose 9.98% year-over-year to $45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.6 million (up 9.98% YoY) and the FY2025 annual result came in at $50.3 million, up 21.42% from the prior year.
- Total Liabilities slipped to $45.6 million in Q1 2026 per SVRA's latest filing, from $50.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $50.3 million in Q4 2025 and bottomed at $29.7 million in Q1 2022.
- The 5-year median for Total Liabilities is $37.2 million (2023), against an average of $37.7 million.
- The widest annual swing landed in 2022, when Total Liabilities fell 8.54%; it then rose 21.42% in 2025.
- Tracing SVRA's Total Liabilities over 5 years: stood at $32.0 million in 2022, then rose by 16.23% to $37.2 million in 2023, then climbed by 11.39% to $41.4 million in 2024, then climbed by 21.42% to $50.3 million in 2025, then declined by 9.34% to $45.6 million in 2026.
- Per Business Quant, the three latest SVRA Total Liabilities figures stand at $45.6 million (Q1 2026), $50.3 million (Q4 2025), and $46.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 45.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.61 Mn |
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.47 Mn |
| Dec 31, 2024 | 41.43 Mn |
| Sep 30, 2024 | 39.47 Mn |
| Jun 30, 2024 | 37.94 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Dec 31, 2023 | 37.19 Mn |
| Sep 30, 2023 | 35.53 Mn |
| Jun 30, 2023 | 32.12 Mn |
| Mar 31, 2023 | 31.10 Mn |
| Dec 31, 2022 | 32.00 Mn |
| Sep 30, 2022 | 31.24 Mn |
| Jun 30, 2022 | 29.74 Mn |
| Mar 31, 2022 | 29.73 Mn |
| Dec 31, 2021 | 32.10 Mn |
| Sep 30, 2021 | 32.05 Mn |
| Jun 30, 2021 | 31.05 Mn |
| Mar 31, 2021 | 32.51 Mn |
| Dec 31, 2020 | 33.36 Mn |
| Sep 30, 2020 | 32.72 Mn |
| Jun 30, 2020 | 31.35 Mn |
| Mar 31, 2020 | 32.66 Mn |
| Dec 31, 2019 | 34.51 Mn |
| Sep 30, 2019 | 33.83 Mn |
| Jun 30, 2019 | 34.53 Mn |
| Mar 31, 2019 | 46.46 Mn |
| Dec 31, 2018 | 44.07 Mn |
| Sep 30, 2018 | 37.27 Mn |
| Jun 30, 2018 | 35.23 Mn |
| Mar 31, 2018 | 35.17 Mn |
| Dec 31, 2017 | 40.32 Mn |
| Sep 30, 2017 | 44.24 Mn |
| Jun 30, 2017 | 46.00 Mn |
| Mar 31, 2017 | 9.54 Mn |
| Dec 31, 2016 | 20.95 Mn |
| Sep 30, 2016 | 26.93 Mn |
| Jun 30, 2016 | 31.25 Mn |
| Mar 31, 2016 | 29.47 Mn |
| Dec 31, 2015 | 30.33 Mn |
| Sep 30, 2015 | 29.90 Mn |
| Jun 30, 2015 | 14.23 Mn |
| Mar 31, 2015 | 12.61 Mn |
| Dec 31, 2014 | 11.84 Mn |
| Sep 30, 2014 | 10.92 Mn |
| Jun 30, 2014 | 9.15 Mn |
| Mar 31, 2014 | 9.57 Mn |
| Dec 31, 2013 | 7.44 Mn |
| Sep 30, 2013 | 6.59 Mn |
| Jun 30, 2013 | 5.94 Mn |
| Mar 31, 2013 | 5.77 Mn |
| Dec 31, 2012 | 5.18 Mn |
| Sep 30, 2012 | 5.27 Mn |
| Jun 30, 2012 | 5.10 Mn |
| Mar 31, 2012 | 4.55 Mn |
| Dec 31, 2011 | 5.08 Mn |
| Sep 30, 2011 | 3.12 Mn |
| Jun 30, 2011 | 3.76 Mn |
| Dec 31, 2010 | 1.80 Mn |